* Neurocrine Biosciences Inc reported quarterly adjusted earnings of $1.24 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 82 cents. The mean expectation of twenty seven analysts for the quarter was for earnings of $1.51 per share. Wall Street expected results to range from $1.26 to $2.12 per share.
* Revenue rose 24.7% to $622.10 million from a year ago; analysts expected $600.63 million.
* Neurocrine Biosciences Inc's reported EPS for the quarter was $1.24.
* The company reported quarterly net income of $129.8 million.
* Neurocrine Biosciences Inc shares had risen by 0.8% this quarter and lost 11.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 18.7% in the last three months.
* In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Neurocrine Biosciences Inc is $168.00 This summary was machine generated from LSEG data October 30 at 01:20 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 1.51 1.24 Missed
Jun. 30 2024 1.05 0.63 Missed
Mar. 31 2024 1.01 0.42 Missed
Dec. 31 2023 1.15 1.44 Beat
Comments